Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QK7Q | ISIN: US76152G1004 | Ticker-Symbol:
NASDAQ
17.05.24
21:58 Uhr
1,670 US-Dollar
-0,040
-2,34 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
REVIVA PHARMACEUTICALS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
REVIVA PHARMACEUTICALS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur REVIVA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrREVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans1
DiReviva Pharmaceuticals Holdings, Inc. reports results for the quarter ended in March - Earnings Summary1
DiReviva Pharmaceuticals GAAP EPS of -$0.253
DiREVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report1
DiREVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report1
MoReviva Pharmaceuticals: Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference2
15.04.Reviva Pharmaceuticals FY Non-GAAP EPS of -$1.65 beats by $0.013
15.04.Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment2
15.04.Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia334- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)...
► Artikel lesen
15.04.REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report1
15.04.Reviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights419- RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia - - Initiation of...
► Artikel lesen
15.04.REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report1
02.04.REVIVA PHARMACEUTICALS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4054
26.03.Reviva Pharmaceuticals: Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting9
11.03.Reviva Pharmaceuticals: Reviva to Present at the UBS Virtual CNS Day5
20.02.Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference1
02.02.Reviva Pharmaceuticals files for $200M mixed securities shelf5
25.01.Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference3
10.01.Reviva Pharmaceuticals: Reviva to Present at Webull LIVE! Healthcare Webinar on January 17589CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to...
► Artikel lesen
20.12.23Italy's distressed assets and NPEs weekly round-up. News from Reviva and more5
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1